Capricor Therapeutics, Inc. (CAPR) Upgraded to Overweight at Cantor Fitzgerald

Market Context

Capricor Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $6.65 with a market capitalization of $1.2B. The stock has declined 17.3% over the past 52 weeks.

Analyst upgrades often act as catalysts for near-term price movement, particularly when they come from major firms with significant institutional following. Cantor Fitzgerald's upgrade suggests their analysts see improving fundamentals, a more favorable risk-reward profile, or upcoming catalysts that could drive the stock higher.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Capricor Therapeutics, Inc.

Among the 10 most recent ratings: 6 Buy, 4 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Aug 14, 2026	Cantor Fitzgerald	Overweight	N/A
Jul 31, 2026	Jones Trading	Hold	N/A
Jul 30, 2026	Piper Sandler	Neutral	N/A
Jul 30, 2026	Cantor Fitzgerald	Neutral	N/A
Jul 30, 2026	HC Wainwright & Co.	Neutral	N/A

Related Tools: Analyst Ratings Dashboard | View CAPR Stock Page